Zimmer Biomet price target raised to $153 from $147 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Zimmer Biomet to $153 from $147 and keeps a Hold rating on the shares. Intra-quarter data points, including the firm’s Q2 hospital survey, increase confidence that procedure momentum will extend beyond Q2 into 2H23 with MedTech companies poised to deliver healthy beat and raises, the analyst tells investors in a research note.